Canadian Children Now Receiving Teplizumab: What It Means for Early Type 1 Diabetes

For the first time in Canada, two children at BC Children's Hospital have received Tzield (teplizumab), a treatment designed to slow the progression of type 1 diabetes in its early stages. This achievement matters because it represents real progress toward something the type 1 diabetes community has pursued for decades: therapies that can change the course of the disease rather than simply manage it after diagnosis.

While a small number of Canadian adults have already received teplizumab since Health Canada approved it in 2025, children are now beginning to benefit as well. This pediatric milestone signals that the treatment is becoming integrated into clinical practice beyond initial rollout.

Teplizumab is designed for people who show early signs of type 1 diabetes but do not yet require insulin therapy. Clinical studies show the drug can delay the onset of insulin-dependent diabetes by a median of about two years in eligible adults and children who receive it.

To be eligible for teplizumab, a person must first be identified through screening as having stage 2 type 1 diabetes—an autoimmune process that is underway but has not yet progressed to insulin dependence. In Canada, the drug is currently approved for children age 8 and above. The U.S. Food and Drug Administration has approved teplizumab for an even younger population: children as young as one year old with stage 2 type 1 diabetes.

For families, a two-year delay in disease progression can be meaningful. It may mean fewer medical emergencies, more time to emotionally and practically prepare for what insulin therapy will involve, and an opportunity to plan ahead rather than respond to crisis.

The shift from waiting for a type 1 diabetes diagnosis to identifying and treating the disease in its earlier stages represents a fundamental change in how the condition is approached—moving toward intervention before insulin becomes necessary, rather than after.

While access to teplizumab remains limited, the fact that Canadian children are now receiving it is an encouraging signal that more people in the type 1 diabetes community may begin to benefit from the first disease-modifying therapy available for the condition.

The expanded approval in the United States for younger children suggests the potential for continued broadening of access in Canada. However, as with any new treatment, teplizumab requires early screening to identify eligible candidates—a process that is still being integrated into standard diabetes care across different health systems.

Origin: breakthrought1d.ca (News report). Evidence: News report, corroborated with 5 indexed studies. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.